Recurrent myocardial infarction (re-MI) is a common event following acute coronary syndrome (ACS), especially during the first year. According to epidemiological studies, patients who experience re-MI are at higher risk of all-cause cardiovascular events and mortality. The cornerstones of re-MI prevention include complete functional coronary revascularization, effective dual antiplatelet therapy and secondary prevention strategies. Notwithstanding this, some controversy still exists on the definition and management of re-MI, and no dedicated studies have been designed or conducted so far in this setting. We here provide an overview of epidemiological and prognostic data on ACS patients experiencing re-MI, along with current available treatment and preventive options.
Cite this article
Current management and prognosis of patients with recurrent myocardial infarction
Leonardo De Luca1,*, Luca Paolucci2, Annunziata Nusca2, Rita Lucia Putini1, Fabio Mangiacapra2, Enrico Natale1, Gian Paolo Ussia2, Furio Colivicchi3, Francesco Grigioni2, Francesco Musumeci4, Domenico Gabrielli1
1 Department of Cardiosciences, Division of Cardiology, A. O. San Camillo-Forlanini, 00152 Rome, Italy
2 Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico University, 00128 Rome, Italy
3 Division of Cardiology, San Filippo Neri Hospital, 00186 Rome, Italy
4 Department of Cardiosciences, Cardiac Surgery Unit and Heart Transplantation Center, A. O. San Camillo-Forlanini, 00152 Rome, Italy
Academic Editor: Peter A. McCullough This article belongs to the Special Issue: Contemporary Management of Special Subsets of Acute Coronary Syndromes Patients ().
Rev. Cardiovasc. Med. 2021 , 22(3), 731–740; https://doi.org/10.31083/j.rcm2203080
Submitted: 30 May 2021 | Revised: 29 July 2021 | Accepted: 4 August 2021 | Published: 24 September 2021
Recurrent myocardial infarction
Acute coronary syndrome
Dual antiplatelet therapy
Percutaneous coronary intervention